Related Experiment Video
Updated: Aug 9, 2026
Embryo Microinjection Techniques for Efficient Site-Specific Mutagenesis in Culex quinquefasciatus
Published on: May 24, 2020
Regulatory challenges: lessons from recent West Nile virus trials in the United States
Penelope M Jester1, Samuel J Tilden, Yufeng Li
1Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Abstract:
Delays in research on emerging infections could deprive the public of appropriate therapies. This report describes challenges encountered in implementing two multicenter protocols of West Nile virus (WNV) infections in the United States during 2003. Protocol development times, federal regulatory approvals, and local Institutional Review Boards (IRB) approvals were compiled. Twenty eight institutions participated in a natural history study and 27 in a therapeutic trial of WNV developed through the National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group (CASG). The CASG compiled protocol development times, federal regulatory approvals, and local IRB approvals. Additional information on the local IRB process was obtained by survey of the investigators. Because of the lengthy development and approval process, protocols were distributed after the start of the epidemic season, most sites were unable to enroll subjects at the peak of the season, and a number of sites lacked IRB approval at the end of the season.
Insights
Delays in research protocols for emerging infections like West Nile virus (WNV) hinder timely public access to therapies. Lengthy approval processes prevented many sites from enrolling patients during peak WNV season.
Area of Science:
- Infectious Diseases
- Clinical Research
- Public Health
Background:
- Emerging infectious diseases require rapid research for effective therapies.
- West Nile virus (WNV) poses a significant public health concern.
- Previous research on WNV has faced implementation challenges.
Purpose of the Study:
- To describe challenges in implementing multicenter WNV research protocols.
- To analyze protocol development and approval timelines.
- To identify barriers to timely subject enrollment in WNV studies.
Main Methods:
- Compiled protocol development times for two WNV studies.
- Collected data on federal and local Institutional Review Board (IRB) approvals.
- Surveyed investigators regarding local IRB processes.
- Analyzed data from 28 institutions for a natural history study and 27 for a therapeutic trial.
Main Results:
- Lengthy protocol development and approval processes were identified as major challenges.
- Protocols were distributed late in the WNV epidemic season.
- Most participating sites could not enroll subjects during the peak season.
- Several sites lacked IRB approval even at the end of the season.
Conclusions:
- The complex and lengthy regulatory and approval process significantly delayed WNV research implementation.
- These delays critically impacted the ability to conduct research during the WNV epidemic's peak.
- Streamlining research protocols and approval processes is crucial for emerging infectious disease research.
